Spots Global Cancer Trial Database for Nexavar Dosing in Renal Cancer Patients in "Real-life" Setting
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Nexavar Dosing in Renal Cancer Patients in "Real-life" Setting
Official Title: Nexavar Dose Evaluation Study in Patients With Advanced Renal Cell Carcinoma
Study ID: NCT01557127
Conditions
Interventions
Study Description
Brief Summary: This study is a registry of renal cancer patients treated with Nexavar. It aims to evaluate the actual dosing of Nexavar in "real-life" setting vs. the prescribed dose.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, Many Locations, , Poland
Contact Details
Name: Bayer Study Director
Affiliation: Bayer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
